About this trial
Intra-articular platelet-rich plasma (PRP) injection is a widely used treatment for knee osteoarthritis, but patients respond to it very differently and there is currently no simple, inexpensive way to predict who will benefit. The neutrophil-to-lymphocyte ratio (NLR) and related indices derived from a routine complete blood count reflect a person's baseline inflammatory state. This prospective single-arm observational cohort study investigates whether the baseline NLR, together with the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII), and the monocyte-to-lymphocyte ratio (MLR), predicts the clinical response to intra-articular PRP in patients with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis. The investigators will enroll 120 patients aged 40 to 60 years, each of whom receives a standardized course of three leukocyte-poor PRP injections one week apart. Patients are followed for 6 months, and the primary clinical outcome is the change in the WOMAC osteoarthritis index at 6 months. Outcome assessors are blinded to patients' blood-count values. If a baseline blood ratio predicts response, it could become a low-cost tool to guide patient selection for PRP.
Eligibility criteria
Qualifiers
Age 40 to 60 years
Symptomatic primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3 on weight-bearing radiographs
Body mass index below 40
Candidate for and scheduled to receive a course of intra-articular platelet-rich plasma for the index knee
Disqualifiers
Systemic inflammatory or autoimmune disease
Active acute infection at the time of enrollment
Current anticoagulant or antiplatelet therapy, or current or recent chemotherapy
Any contraindication to platelet-rich plasma per the 2025 GRIIP recommendations
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Utku Gürhan
Lead sponsor
University of Kyrenia
Sponsor institution